OTS.at - aktuelle Inhalte in Text, Bild, Ton und Video

Servier

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Suresnes, France (OTE) - Suresnes, France (ots/PRNewswire)

08.09.2025, 09:44:32
/
OTE0001

Servier

Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio

Paris (ots/PRNewswire) - Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers...

09.03.2023, 07:31:11
/
OTE0001

Servier

Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

Paris (ots/PRNewswire) - Servier, a global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...

24.02.2023, 13:12:03
/
OTE0003

Servier

Servier full year 2021

22 results confirm the transformation trajectory of the Group

02.02.2023, 07:31:02
/
OTE0002

Servier

Servier unveils its 2030 ambition and reveals a new visual identity

Paris (ots/PRNewswire) - * A new ambition by 2030 to accelerate its transformation dynamic

06.10.2022, 07:31:07
/
OTE0001

Servier

Servier submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma

Paris (ots/PRNewswire) - - TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme

10.03.2022, 14:49:35
/
OTE0002

Servier

Servier to Acquire Agios Pharmaceuticals' Oncology Business

Paris and Boston (ots/PRNewswire) - - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties

21.12.2020, 13:59:52
/
OTE0005

Servier

Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972

S201086 in knee osteoarthritis patients

15.10.2020, 22:19:01
/
OTE0005

Servier

Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Thousand Oaks, Calif., South San Francisco, Calif., and Suresnes, France (ots/PRNewswire) - - Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events

08.10.2020, 15:29:18
/
OTE0007

Servier

Servier schließt Übernahme von Symphogen ab

Paris (ots/PRNewswire) - Servier, ein unabhängiges internationales Pharmaunternehmen gibt den Abschluss der Übernahme von Symphogen A/S bekannt, das nun als Antikörper-Kompetenzzentrum von Servier in verschiedenen...